MTOR and prostate carcinoma: In prostate cancer, docetaxel treatment repressed KLF5 expression via AMPK/mTOR/p70S6K signaling pathway, which may lead to increased BECN1 expression, induction of cell autophagy and promotion of cell survival (Figure 8B).